A mechanistic systems pharmacology model for prediction of LDL cholesterol lowering by PCSK9 antagonism in human dyslipidemic populations

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 11, 2014, Pages

  Gadkar, K ^a   Budha, N ^a   Baruch, A ^a   Davis, J D ^a   Fielder, P ^a   Ramanujan, S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN LIKE KEXIN TYPE 9; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; CALIBRATION; DRUG DOSE REGIMEN; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INHIBITION; HUMAN; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION; VALIDATION PROCESS;

EID: 84927767305     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.47     Document Type: Article

References (40)

1. Duff, C.J. & Hooper, N.M. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin. Ther. Targets 15, 157-168 (2011).
2. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K. & Hobbs, H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165 (2005).
3. Hooper, A.J. & Burnett, J.R. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin. Biol. Ther. 13, 429-435 (2013).
4. Giugliano, R.P. et al.; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebocontrolled, dose-ranging, phase 2 study. Lancet 380, 2007-2017 (2012).
5. McKenney, J.M., Koren, M.J., Kereiakes, D.J., Hanotin, C., Ferrand, A.C. & Stein, E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/ kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353 (2012).
6. Dias, C.S. et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60, 1888-1898 (2012).
7. Stein, E.A. et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380, 29-36 (2012).
8. Roth, E.M., McKenney, J.M., Hanotin, C., Asset, G. & Stein, E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367, 1891-1900 (2012).
9. Raal, F. et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126, 2408-2417 (2012).
10. Tingley, W. et al. Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study Eur Heart J 34(suppl 1) P4183 (2013).
11. van der Graaf, P.H. & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011).
12. Peterson, M.C. & Riggs, M.M. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46, 49-63 (2010).
13. Rullmann, J.A., Struemper, H., Defranoux, N.A., Ramanujan, S., Meeuwisse, C.M. & van Elsas, A. Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. Syst. Biol. (Stevenage). 152, 256-262 (2005).
14. Kirouac, D.C. et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci. Signal. 6, ra68 (2013).
15. Nissen, S.E. et al.; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071-1080 (2004).
16. Stern, R.H., Yang, B.B., Hounslow, N.J., MacMahon, M., Abel, R.B. & Olson, S.C. Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 40, 616-623 (2000).
17. Careskey, H.E., Davis, R.A., Alborn, W.E., Troutt, J.S., Cao, G. & Konrad, R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49, 394-398 (2008).
18. Dubuc, G. et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454-1459 (2004).
19. Mayne, J. et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 7, 22 (2008).
20. Zhang, L. et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int. J. Biol. Sci. 8, 310-327 (2012).
21. Leigh, S.E., Foster, A.H., Whittall, R.A., Hubbart, C.S. & Humphries, S.E. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann. Hum. Genet. 72, 485-498 (2008).
22. Raal, F., Panz, V., Immelman, A. & Pilcher, G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to highdose statin therapy. J. Am. Heart Assoc. 2, e000028 (2013).
23. Shoda, L. et al. The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin. Exp. Immunol. 161, 250-267 (2010).
24. Schmidt, B.J., Casey, F.P., Paterson, T. & Chan, J.R. Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis. BMC Bioinformatics 14, 221 (2013).
25. Gutenkunst, R.N., Waterfall, J.J., Casey, F.P., Brown, K.S., Myers, C.R. & Sethna, J.P. Universally sloppy parameter sensitivities in systems biology models. PLoS Comput. Biol. 3, 1871-1878 (2007).
26. Stein, E.A. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108-1118 (2012).
27. Mohammadpour, A.H. & Akhlaghi, F. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin. Pharmacokinet. 52, 615-626 (2013).
28. Barter, P. & Rye, K.A. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Trends Pharmacol. Sci. 32, 694-699 (2011).
29. Lefer, D.J. Statins as potent antiinflammatory drugs. Circulation 106, 2041-2042 (2002).
30. Sacks, F.M. & Campos, H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J. Clin. Endocrinol. Metab. 88, 4525-4532 (2003).
31. Bosner, M.S., Lange, L.G., Stenson, W.F. & Ostlund, R.E. Jr. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. 40, 302-308 (1999).
32. Sudhop, T. et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J. Lipid Res. 50, 2117-2123 (2009).
33. Cromwell, W.C. et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J. Clin. Lipidol. 1, 583-592 (2007).
34. Havel, R.J. The formation of LDL: mechanisms and regulation. J. Lipid Res. 25, 1570-1576 (1984).
35. Horton, J.D. et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U.S.A. 100, 12027-12032 (2003).
36. Horton, J.D., Cohen, J.C. & Hobbs, H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71-77 (2007).
37. Chan, D.C., Lambert, G., Barrett, P.H., Rye, K.A., Ooi, E.M. & Watts, G.F. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin. Chem. 55, 2049-2052 (2009).
38. Osono, Y., Woollett, L.A., Herz, J. & Dietschy, J.M. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J. Clin. Invest. 95, 1124-1132 (1995).
39. Mc Auley, M.T., Wilkinson, D.J., Jones, J.J. & Kirkwood, T.B. A whole-body mathematical model of cholesterol metabolism and its age-associated dysregulation. BMC Syst. Biol. 6, 130 (2012).
40. Mager, D.E. & Jusko, W.J. General pharmacokinetic model for drugs exhibiting targetmediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28, 507-532 (2001).